Acasti Pharma Awarded Composition-of-Matter Patents for GTX-101 in Europe, China and Mexico and for GTX-102 in Japan

Acasti Pharma Announces Initiation of Pharmacokinetic Bridging Study for GTX-104, the Company’s Lead Drug Candidate for the Treatment of Subarachnoid Hemorrhage

The Oppenheimer Fall Healthcare Summit

Sep 21, 2021 • 2:05 pm EDT

H.C. Wainwright 23rd Annual Global Investment Conference

Sep 13 – Sep 15, 2021